SmartMed Technologies expands Cellular Analysis Lab at Seoul facility

SmartMed Technologies today announced the opening of its expanded state-of-the-art Cellular Analysis Lab at its Biomedical facility in Seoul.

Online PR News – 29-April-2021 – YEONGDEUNGPO-GU/SEOUL – SmartMed Technologies’ expanded facility will have high end machinery capable of high content screening which enables it to do real time analysis of cells especially in projects exploring novel bio-molecular science, oncology, neuroscience and rare diseases.

SmartMed Technologies’ Chief Technology Officer, Mr. Bayard Donovan commented on the expanded Cellular Analysis Lab saying “This extended facility will have sophisticated machinery which will be able to deliver a range of projects including genetic and pharmacological validation studies and also the ability to develop a variety of cellular target engagement assays and in vitro biomarker assessments.”

"Our Research and Development team will be able to perform carefully executed experiments and deliver the data in an accurate and more timely manner, with their technical expertise contributing to the experimental design and interpretation of results which will ultimately enable us to rapidly generate critical data for our drug discovery programs," added Bayard Donavan, Chief Technology Officer of SmartMed Technologies.

About Us - SmartMed Technologies

SmartMed Technologies is a pioneering bioinformatics medical research and development company focused on delivering innovative medical products through artificial intelligence technology to combat prevalent, rare and emerging diseases.

Based in Seoul, our team collects and analyzes big data, utilizing artificial intelligence to gain insight into complex diseases such as leukemia and different cancers. Our approach centers on genome integration with high-performance computers and deep artificial intelligence learning.

With our advanced technology, we have been able to cut costs arising from industry trial-and-error procedures; with the integration of supercomputers into our work, we are able to run more comprehensive simulations, better target proteins, discover new drug compounds for a multitude of diseases, and generally increase our capacity for successful drug development.

With international recognition for our research and projects, some in collaboration with world-renowned institutions, we consistently aim to develop our understanding in the medical field through artificial intelligence and advanced clinical trials.